<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00631566</url>
  </required_header>
  <id_info>
    <org_study_id>IDCRP-003-RV210</org_study_id>
    <nct_id>NCT00631566</nct_id>
  </id_info>
  <brief_title>Prospective Study of Methicillin-Resistant Staphylococcus Aureus (MRSA) Among HIV-Infected Persons</brief_title>
  <acronym>MRSA</acronym>
  <official_title>Prospective Study on the Incidence, Predictors, and Characteristics of Methicillin-Resistant Staphylococcus Aureus Infections and a Randomized, Double-Blind Study on Decolonization Procedures for Prevention of MRSA Infections Among HIV-Infected Persons</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uniformed Services University of the Health Sciences</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Infectious Diseases Clinical Research Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>US Military HIV Research Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Uniformed Services University of the Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will prospectively evaluate the prevalence and incidence (over a two year period)
      of MRSA colonization and infection among HIV-infected military beneficiaries to determine
      predictors for the development of MRSA colonization and infection. This study will also
      investigate the utility of decolonization procedures for clearance of MRSA carriage and
      prevention of MRSA infections. Finally, the molecular characteristics and the antimicrobial
      sensitivities of isolates in this population will be determined.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Actual">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The presence of MRSA on repeated swabs to assess the efficacy of these medications on clearing MRSA colonization</measure>
    <time_frame>Every 4 weeks for 5 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the prevalence and incidence of MRSA colonization of the nares, throat, perirectal, axilla, and groin areas among HIV infected patients and to study changes in the colonization rates over time.</measure>
    <time_frame>Every 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the change in CD4 counts and HIV viral loads during the time of a MRSA or soft tissue infection.</measure>
    <time_frame>At time of infection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the molecular characteristics and the antimicrobial sensitivities of MRSA isolates in this population.</measure>
    <time_frame>at time of positive MRSA results</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">550</enrollment>
  <condition>HIV Infections</condition>
  <condition>Staphylococcal Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mupirocin (Bactroban) 2%; hexachlorophene (pHisoHex) 3%</intervention_name>
    <description>BACTROBAN NASAL is a white to off-white ointment that contains 2.15% w/w mupirocin calcium (equivalent to 2.0% pure mupirocin free acid) in a soft white ointment base. The inactive ingredients are paraffin and a mixture of glycerin esters (SOFTISAN 649).
pHisoHex, brand of hexachlorophene detergent cleanser, is an antibacterial sudsing emulsion for topical administration.
Some randomized patients will receive mupirocin (Bactroban) nasal ointment plus hexachlorophene (pHisoHex) body washes for seven days.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Some randomized patients will receive a placebo nasal ointment (white petroleum) and a placebo body soap with no antimicrobial activity for seven days.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults (at least 18 years of age) who are HIV positive by a reactive screening (ELISA,
             EIA) and a confirmatory test (Western blot) and who are able to attend the study
             visits which are every 6 months (+/- 2 months), at the minimum

        Exclusion Criteria:

          -  Known allergy to mupirocin (Bactroban®) nasal ointment or hexachlorophene (pHisoHex®)
             soaps or constituents of these products.

          -  Age less than 18 years.

          -  Inability to remain in the study for the two year duration.

          -  Pregnant or breastfeeding females.

          -  Females who intend to become pregnant during the two year study time period.

          -  Persons who are healthcare providers with direct patient contact.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Naval Medical Center San Diego/Infectious Disease Division</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92134-1201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walter Reed National Military Medical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20889</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Antonio Military Medical Center (BAMC/WHMC)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78236-9908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Naval Medical Center Portsmouth</name>
      <address>
        <city>Portsmouth</city>
        <state>Virginia</state>
        <zip>23708-2197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Crum-Cianflone NF, Shadyab AH, Weintrob A, Hospenthal DR, Lalani T, Collins G, Mask A, Mende K, Brodine SK, Agan BK; Infectious Disease Clinical Research Program HIV Working Group. Association of methicillin-resistant Staphylococcus aureus (MRSA) colonization with high-risk sexual behaviors in persons infected with human immunodeficiency virus (HIV). Medicine (Baltimore). 2011 Nov;90(6):379-89. doi: 10.1097/MD.0b013e318238dc2c.</citation>
    <PMID>22033452</PMID>
  </results_reference>
  <results_reference>
    <citation>Vyas KJ, Shadyab AH, Lin CD, Crum-Cianflone NF. Trends and factors associated with initial and recurrent methicillin-resistant Staphylococcus aureus (MRSA) skin and soft-tissue infections among HIV-infected persons: an 18-year study. J Int Assoc Provid AIDS Care. 2014 May-Jun;13(3):206-13. doi: 10.1177/2325957412473780. Epub 2013 Apr 19.</citation>
    <PMID>23603632</PMID>
  </results_reference>
  <results_reference>
    <citation>Weintrob A, Bebu I, Agan B, Diem A, Johnson E, Lalani T, Wang X, Bavaro M, Ellis M, Mende K, Crum-Cianflone N. Randomized, Double-Blind, Placebo-Controlled Study on Decolonization Procedures for Methicillin-Resistant Staphylococcus aureus (MRSA) among HIV-Infected Adults. PLoS One. 2015 May 27;10(5):e0128071. doi: 10.1371/journal.pone.0128071. eCollection 2015.</citation>
    <PMID>26018036</PMID>
  </results_reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2008</study_first_submitted>
  <study_first_submitted_qc>March 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2008</study_first_posted>
  <last_update_submitted>June 13, 2017</last_update_submitted>
  <last_update_submitted_qc>June 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Uniformed Services University of the Health Sciences</investigator_affiliation>
    <investigator_full_name>Brian Agan</investigator_full_name>
    <investigator_title>Deputy Science Director, IDCRP</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Methicillin-resistant Staphylococcus aureus (MRSA)</keyword>
  <keyword>HIV and Staphylococcus aureus infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Staphylococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methicillin</mesh_term>
    <mesh_term>Mupirocin</mesh_term>
    <mesh_term>Hexachlorophene</mesh_term>
    <mesh_term>Triclosan</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>November 30, 2017</submitted>
    <returned>December 19, 2017</returned>
    <submitted>December 20, 2017</submitted>
    <returned>January 19, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

